Cysteine variants of interleukin-11
AssigneeBolder Biotechnology, Inc.
InventorGeorge N. Cox, III
Life of this patent
Estimating the term…
Abstract
Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
Claims22
A mutein of IL-11 of SEQ ID NO:17, wherein a cysteine residue is substituted for an amino acid selected from the group consisting of P22, G23, P24, G27 and A162 wherein the mutein retains biological activity.
A cysteine mutein of IL-11 of SEQ ID NO:17, wherein P22 is deleted and wherein the mutein comprises two cysteine substitutions, wherein cysteine residues are substituted for amino acids in SEQ ID NO:17 selected from the group consisting of P25 and T77, P25 and S117, P25 and S165, P24 and P25, D69 and T77, and A162C and S165C, wherein the mutein retains biological activity.
A mutein of IL-11 of SEQ ID NO:17, wherein amino acid P22 is deleted and wherein a cysteine residue is substituted for at least one amino acid selected from the group consisting of P24, P25, E38, L39, D69, L72, S74, T77, A114, S117, E123, A148, and S165, wherein the mutein retains biological activity.
A mutein of IL-11 of SEQ ID NO:17, wherein amino acids 22-26 are deleted and wherein the mutein retains biological activity.
A mutein of IL-11 of SEQ ID NO:17, wherein amino acids 22-29 are deleted and wherein the mutein retains biological activity.
Dependencies are inferred from the claim text.